Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOMENICA first-line MMR-deficient advanced or metastatic endometrial cancer trial
ISRCTN16573769Phase 3Active, not recruiting
- Sponsor
- Arcagy-Gineco
- Start
- Mar 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial in endometrial adenocarcinoma and endometrial cancer (EC) comparing Dostarlimab with Carboplatin + paclitaxel (2 arms). Primary endpoint: Progression-free survival. Started Mar 2024; status: active, not recruiting.
02
Drugs
dostarlimabcarboplatinpaclitaxel
03
Conditions
endometrial adenocarcinomaendometrial cancer (EC)
Beyond the preview
Go deeper on ISRCTN16573769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN16573769.